Literature DB >> 11177675

Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

H Seggewiss1.   

Abstract

Since the early 1960s, surgical myotomy-myectomy has been the standard treatment for patients with drug-refractory symptoms due to hypertrophic cardiomyopathy and dynamic outflow tract obstruction. Comparable morphologic and functional results can be achieved by percutaneous septal ablation (PTSMA) by alcohol-induced septal branch occlusion. The circumscribed therapeutic myocardial infarction results in widening of the left ventricular outflow tract with consecutive gradient reduction. Follow-up studies show clinical and objective improvement as well as further gradient reduction due to left ventricular remodeling. In this article, an updated review of the latest results of PTSMA is provided.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11177675     DOI： 10.1007/s11886-001-0044-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  31 in total

1.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area.

Authors:  L Faber; H Seggewiss; P Ziemssen; U Gleichmann
Journal:  Catheter Cardiovasc Interv       Date:  1999-08       Impact factor: 2.692

2.  Genes and disease expression in hypertrophic cardiomyopathy.

Authors:  W J McKenna; F Coccolo; P M Elliott
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

3.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

4.  Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report.

Authors:  H Seggewiss; L Faber; W Meyners; N Bogunovic; H J Odenthal; U Gleichmann
Journal:  Cathet Cardiovasc Diagn       Date:  1998-05

5.  Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction.

Authors:  H Seggewiss; L Faber
Journal:  Eur J Echocardiogr       Date:  2000-12

6.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients.

Authors:  L Faber; A Meissner; P Ziemssen; H Seggewiss
Journal:  Heart       Date:  2000-03       Impact factor: 5.994

7.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

8.  [Catheter treatment of hypertrophic obstructive cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  Dtsch Med Wochenschr       Date:  1996-05-24       Impact factor: 0.628

9.  Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy.

Authors:  R C Robbins; E B Stinson
Journal:  J Thorac Cardiovasc Surg       Date:  1996-03       Impact factor: 5.209

Review 10.  Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment.

Authors:  J M Curtius; J Stoecker; B Loesse; R Welslau; D Scholz
Journal:  Cardiology       Date:  1989       Impact factor: 1.869
View more
  10 in total

Review 1.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

2.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

Review 3.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

4.  Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Silke Daci; Barbara Pfeiffer; Konstadia Papadopoulou; Anna Neugebauer; Hubert Seggewiss
Journal:  Clin Res Cardiol       Date:  2016-06-06       Impact factor: 5.460

5.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

Review 6.  Experimental therapies in hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  J Cardiovasc Transl Res       Date:  2009-10-01       Impact factor: 4.132

Review 7.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

Review 9.  Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelos G Rigopoulos; Hubert Seggewiss
Journal:  Curr Cardiol Rev       Date:  2016

Review 10.  Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Authors:  Lothar Faber
Journal:  Adv Med       Date:  2014-05-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.